nach oben

Erschienen in:

14.06.2021 | Original Article

Evaluation of serum interleukin-6 (IL-6), IL-13, and IL-17 levels and computed tomography finding in interstitial lung disease associated with connective tissue disease patients

verfasst von: Dilek Tezcan, Abdullah Sivrikaya, Dilek Ergün, Halil Özer, Duygu Eryavuz Onmaz, Muslu Kazım Körez, Turan Akdağ, Semral Gülcemal, Muhammet Limon, Sema Yılmaz

Erschienen in: Clinical Rheumatology | Ausgabe 11/2021

Einloggen, um Zugang zu erhalten

Abstract

Objective

Interstitial lung disease (ILD) is one of the most severe complications which is associated with connective tissue disease (CTD) and causes to morbidity and mortality. So, we aimed to determine serum levels of interleukin-6 (IL-6), IL-13, and IL-17, to investigate whether these cytokines are related to CTD-ILD, and to find their possible contribution to determining the prognosis of the disease.

Methods

A total of 150 participants, 80 patients diagnosed with CTD-ILD (mean age, 58.21 ± 12.36) and 70 healthy controls (mean age, 57.07 ± 9.60) were recruited from the rheumatology department between January 2016 and June 2019 in the study. High-resolution computed tomography (HRCT) findings were scored as similarly to previous studies. Serum IL-6, IL 13, and IL-17 levels were measured by ELISA test kits.

Results

The levels of IL-6, IL-13, and IL-17 in CTD patients were significantly higher than the healthy individuals (p < 001), but the HRCT score’s relation were not determined. IL-6 was associated with disease duration and disease activity scores of DAS28, ESDAII, and dSSc. There was a significant relation between dSSc, HCRT fibrosis, and total score.CRP, hemoglobin, and platelets were associated with the HRCT inflammation pattern.

Conclusion

At the study, it has been observed that serum IL-13, IL-6 and IL-17 levels are increased in patients with CTD-ILD. Besides, IL-6 was associated with disease activity scores of DAS28, ESDAII, and dSSc. Also, HRCT fibrosis score is associated with dSSc. Further and comprehensive studies are needed to understand better the complex intersection of lung disease with systemic autoimmunity.

Key Points

• Serum IL-13, IL-6, and IL-17 levels are increased in patients with CTD-ILD.

• IL-6 was associated with disease activity scores of DAS28, ESDAII, and diffuse skin involvement.

• HRCT fibrosis score is associated with diffuse skin involvement in patients with SSc-ILD.

• HRCT inflammation score is associated with PAH.

Nur mit Berechtigung zugänglich

Koo S-M, Soo-Taek Uh (2017) Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist’s point of view. Korean J Intern Med 32(4):600–610. https://doi.org/10.3904/kjim.2016.212CrossRefPubMedPubMedCentral

Ha Y-J, Lee YJ, Kang EH (2018) Lung ınvolvements in rheumatic diseases: update on the epidemiology, pathogenesis, clinical features, and treatment. Biomed Res Int 2018:6930297. https://doi.org/10.1155/2018/6930297CrossRefPubMedPubMedCentral

Wells A, Devaraj A, Renzoni EA, Denton CP (2019) Multidisciplinary evaluation in patients with lung disease associated with connective tissue disease. Semin Respir Crit Care Med 40(2):184–193. https://doi.org/10.1055/s-0039-1684020CrossRefPubMed

Enomoto N, Egashira R, Tabata K, Hashisako M, Kitani M et al (2019) Analysis of systemic lupus erythematosus-related interstitial pneumonia: a retrospective multicentre study. Sci Rep 9(1):7355. https://doi.org/10.1038/s41598-019-43782-7CrossRefPubMedPubMedCentral

De Lauretis A, Veeraraghavan S, Renzoni E (2011) Review series: aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis 8(1):53–82. https://doi.org/10.1177/1479972310393758CrossRefPubMed

Koo SM, Kim SY, Choi SM, Lee HK (2019) Korean guidelines for diagnosis and management of ınterstitial lung diseases: part 5. Connective tissue disease-associated ınterstitial lung disease. Tuberc Respir Dis 82(4):285–297. https://doi.org/10.4046/trd.2019.0009CrossRef

Manfredi A, Sebastiani M, Cerri S, Vacchi C, Tonelli R, Della Casa G, Cassone G, Spinella A, Fabrizio P, Luppi F, Salvarani C (2019) Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature. J Thorac Dis 11(4):1621–1628. https://doi.org/10.21037/jtd.2019.03.28CrossRefPubMedPubMedCentral

Bes C (2018) Comprehensive review of current diagnostic and treatment approaches to interstitial lung disease associated with rheumatoid arthritis. Eur J Rheumatol 6(3):146–149. https://doi.org/10.5152/eurjrheum.2019.19036CrossRefPubMedPubMedCentral

Passalacqua G, Mincarini M, Colombo D, Troisi G, Ferrari M, Bagnasco D, Balbi F, Riccio A, Canonica GW (2017) IL-13 and idiopathic pulmonary fibrosis: possible links and new therapeutic strategies. Pulm Pharmacol Ther 45:95–100. https://doi.org/10.1016/j.pupt.2017.05.007CrossRefPubMed

10.

Brown Lobbins ML, Shivakumar BR, Postlethwaite AE, Hasty KA (2018) Chronic exposure of interleukin-13 suppress the induction of matrix metalloproteinase-1 by tumour necrosis factor α in normal and scleroderma dermal fibroblasts through protein kinase B/Akt. Clin Exp Immunol 191(1):84–95. https://doi.org/10.1111/cei.13045CrossRefPubMed

11.

Ganesan R, Rasool M (2017) Interleukin 17 regulates SHP-2, and IL-17RA/STAT-3 dependent Cyr 61, IL-23 and GM-CSF expression RANKL mediated osteoclastogenesis by fibroblast-like synoviocytes in rheumatoid arthritis. Mol Immunol. 91:134–144. https://doi.org/10.1177/1479972310393758CrossRefPubMed

12.

Assayag D, Kaduri S, Hudson M, Baron M (2012) High-resolution computed tomography scoring systems for evaluating ınterstitial lung disease in systemic sclerosis patients. Rheumatology. https://doi.org/10.4172/2161-1149.S1-003CrossRef

13.

Jeganathan N, Sathananthan M (2020) Connective tissue disease-related ınterstitial lung disease: prevalence, patterns, predictors, prognosis, and treatment. Lung 198(5):735–759. https://doi.org/10.1007/s00408-020-00383-wCrossRefPubMed

14.

Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J (2020) Etiology, risk factors, and biomarkers in systemic sclerosis with ınterstitial lung disease. Am J Respir Crit Care Med 201(6):650–660. https://doi.org/10.1164/rccm.201903-0563CICrossRefPubMedPubMedCentral

15.

Bonhomme O, André B, Gester F, de Seny D, Moermans C, Struman I, Louis R, Malaise M, Guiot J (2019) Biomarkers in systemic sclerosis-associated interstitial lung disease: a review of the literature. Rheumatology (Oxford) 58(9):1534–1546. https://doi.org/10.1093/rheumatology/kez230CrossRef

16.

Dufour AM, Alvarez M, Russo B, Chizzolini C (2018) Interleukin-6 and type-I collagen production by systemic sclerosis fibroblasts are differentially regulated by ınterleukin-17A in the presence of transforming growth factor-beta 1. Front Immunol 9:1865. https://doi.org/10.3389/fimmu.2018.01865CrossRefPubMedPubMedCentral

17.

Hinchcliff M, O’Reilly S (2020) Current and potential new targets in systemic sclerosis therapy: a new hope. Curr Rheumatol Rep 22(8):42. https://doi.org/10.1007/s11926-020-00918-3CrossRefPubMedPubMedCentral

18.

Ding J, Su S, You T, Xia T, Lin X, Chen Z, Zhang L (2020) Serum interleukin-6 level is correlated with the disease activity of systemic lupus erythematosus: a meta-analysis. Clinics (Sao Paulo) 75:e1801. https://doi.org/10.6061/clinics/2020/e1801CrossRef

19.

Zhu HL, DU Q, Chen WL, Zuo XX, Li QZ, Liu SJ (2019) [Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms]. Beijing Da Xue Xue Bao Yi Xue Ban 51(4):716–722. Chinese. https://doi.org/10.19723/j.issn.1671-167X.2019.04.021.

20.

Olewicz-Gawlik A, Danczak-Pazdrowska A, Kuznar-Kaminska B, Gornowicz-Porowska J, Katulska K, Trzybulska D, Batura-Gabryel H, Silny W, Poplawski D, Hrycaj P (2014) Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis. Int J Rheum Dis 17(6):664–670. https://doi.org/10.1111/1756-185X.12290CrossRefPubMed

21.

Lee YS, Kim HC, Lee BY, Lee CK, Kim MY, Jang SJ, Lee HS, Moon J, Colby TV, Kim DS (2016) The value of biomarkers as predictors of outcome in patients with rheumatoid arthritis-associated usual ınterstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 33(3):216–223PubMed

22.

Shima Y (2019) The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis. Mod Rheumatol 29(2):294–301. https://doi.org/10.1080/14397595.2018.1559909CrossRefPubMed

23.

Zhang J, Wang D, Wang L, Wang S, Roden AC, Zhao H, Li X, Prakash YS, Matteson EL, Tschumperlin DJ, Vassallo R (2019) Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A/IL-17RA in human fibrotic interstitial lung disease. Am J Physiol Lung Cell Mol Physiol 316(3):L487–L497. https://doi.org/10.1152/ajplung.00301.2018CrossRefPubMed

24.

Sparks JA, He X, Huang J, Fletcher EA, Zaccardelli A, Friedlander HM, Gill RR, Hatabu H, Nishino M, Murphy DJ, Iannaccone CK, Mahmoud TG, Frits ML, Lu B, Rosas IO, Dellaripa PF, Weinblatt ME, Karlson EW, Shadick NA, Doyle TJ (2019) Rheumatoid arthritis disease activity predicting ıncident clinically apparent rheumatoid arthritis-associated ınterstitial lung disease: a prospective cohort study. Arthritis Rheumatol 71(9):1472–1482. https://doi.org/10.1002/art.40904CrossRefPubMedPubMedCentral

25.

Luppi F, Sebastiani M, Silva M, Sverzellati N, Cavazza A, Salvarani C, Manfredi A (2020) Interstitial lung disease in Sjögren’s syndrome: a clinical review. Clin Exp Rheumatol 126(4):291–300

26.

Mahlios J, Zhuang Y (2011) Contribution of IL-13 to early exocrinopathy in Id3-/- mice. Mol Immunol 49(1–2):227–233. https://doi.org/10.1016/j.molimm.2011.08.012CrossRefPubMedPubMedCentral

27.

Yasuda H, Ikeda T, Hamaguchi Y, Furukawa F (2017) Clinically amyopathic dermatomyositis with rapidly progressive interstitial pneumonia: the relation between the disease activity and the serum interleukin-6 level. J Dermatol 44(10):1164–1167. https://doi.org/10.1111/1346-8138.13887.DOI:10.1111/1346-8138.13887

28.

Kawasumi H, Gono T, Kawaguchi Y, Kaneko H, Katsumata Y, Hanaoka M, Kataoka S, Yamanaka H (2014) IL-6, IL-8, and IL-10 are associated with hyperferritinemia in rapidly progressive interstitial lung disease with polymyositis/dermatomyositis. Biomed Res Int 2014:815245. https://doi.org/10.1155/2014/815245CrossRefPubMedPubMedCentral

29.

De Paepe B, Zschüntzsch J (2015) Scanning for therapeutic targets within the cytokine network of ıdiopathic ınflammatory myopathies. Int J Mol Sci 16(8):18683–713. https://doi.org/10.3390/ijms160818683CrossRefPubMedPubMedCentral

30.

Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF (2013) Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res Ther 15(4):R97. https://doi.org/10.1186/ar4277CrossRefPubMedPubMedCentral

31.

Kattah NH, Newell EW, Jarrell JA, Chu AD, Xie J, Kattah MG, Goldberger O, Ye J, Chakravarty EF, Davis MM, Utz PJ (2015) Tetramers reveal IL-17-secreting CD4+ T cells that are specific for U1–70 in lupus and mixed connective tissue disease. Proc Natl Acad Sci U S A 112(10):3044–3049. https://doi.org/10.1073/pnas.1424796112CrossRefPubMedPubMedCentral

Titel: Evaluation of serum interleukin-6 (IL-6), IL-13, and IL-17 levels and computed tomography finding in interstitial lung disease associated with connective tissue disease patients
verfasst von: Dilek Tezcan
Abdullah Sivrikaya
Dilek Ergün
Halil Özer
Duygu Eryavuz Onmaz
Muslu Kazım Körez
Turan Akdağ
Semral Gülcemal
Muhammet Limon
Sema Yılmaz
Publikationsdatum: 14.06.2021
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 11/2021
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-021-05773-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2021

Disease activity indices in psoriatic arthritis: current and evolving concepts

Antibody responses after documented COVID-19 disease in patients with autoimmune rheumatic disease

Myocardial involvement in idiopathic inflammatory myopathies: a multi-center cross-sectional study in the CRDC-MYO Registry

Correction to: An analysis of scientometric data and publication policies of rheumatology journals

Prevalence and risk factors for left ventricular diastolic dysfunction in systemic sclerosis: a multi-center study of CRDC cohort in China